Release Date: October 31, 2025
Expiration Date: October 31, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned ophthalmologists and optometrists to discuss managing ocular toxicities associated with select antibody-drug conjugates, monoclonal antibodies, and selective estrogen receptor degraders to optimize patient outcomes and to improve collaborative, multidisciplinary care, including shared decision-making, that enables the cancer care team to monitor and manage the various ocular toxicities associated with these therapies.
This educational activity is an archive of the live symposium held on September 27, 2025.
Target Audience
This educational activity is directed toward ophthalmologists, oncologists, optometrists, and other health care professionals who would be involved in the management of patients with ocular toxicities secondary to cancer treatment.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Review clinical trial data on the efficacy and safety of oncology drugs associated with ocular toxicities
- Outline approaches for early detection, monitoring, and management of ocular adverse events in patients receiving targeted therapies
- Coordinate multidisciplinary strategies that support collaborative care between oncology and ophthalmology teams in managing ocular toxicities
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here